Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting.

Taku KikuchiNobuhiro TsukadaKodai KunisadaChiaki MatsumotoMoe Nomura-YogoYuki OdaKota SatoTomomi TakeiMizuki OguraYu AbeKenshi SuzukiOsamu HosoyaTadao Ishida

Published in: Hematological oncology (2024)

Keyphrases

multiple myeloma
low dose
high dose
nucleic acid
type diabetes
newly diagnosed
adipose tissue
insulin resistance